Migraine treatments show significant efficacy in new clinical data

At the 40th National Congress of the Italian Society for the Study of Headaches in Lecce, experts highlighted a therapeutic revolution in migraine treatment. New anti-CGRP drugs, including monoclonal antibodies and oral gepants, have significantly improved patient outcomes.

Data presented shows that while previous therapies only halved attacks for 15-20% of patients, modern anti-CGRP treatments achieve a 50% reduction in 60-70% of patients. Furthermore, nearly one-third of patients experience a 75% reduction in crises. Gepants, which are taken orally, offer the ability to both treat acute attacks and prevent future ones, with a low discontinuation rate due to side effects.

Despite these advancements, reports indicate that access to these treatments in Italy remains limited by complex procedures and mandatory preventive therapy requirements, which can delay care and increase social costs.